A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction
The serial markers, acute myocardial infarction and rapid treatment trial (SMARTT)
W. Brian Gibler, MD,
James W. Hoekstra, MD,
W. Douglas Weaver, MD,
Mitchell W. Krucoff, MD,
Alfred P. Hallstrom, PhD,
Raymond E. Jackson, MD,
Michael R. Sayre, MD,
James Christenson, MD,
George L. Higgins, MD,
Grant Innes, MD,
Richard J. Harper, MD,
Gary P. Young, MD,
Nathan R. Every, MD for the SMARTT Investigators*
View larger version (21K):
[in a new window]
|
Figure 1 Patient flow and follow-up diagram. (Discharged = D/Ced)
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Discharge diagnoses: All trial patients, comparing stat versus control groups. P = NS for all comparisons.
|
|
View larger version (15K):
[in a new window]
|
Figure 3 Electrocardiographic findings in all patients with AMI, comparing stat versus control groups.
|
|
View larger version (17K):
[in a new window]
|
Figure 4 Hospital disposition: all trial patients, comparing stat versus control groups.
|
|
|
